
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics PLC is focused on developing advanced T-cell therapies for cancer, with a promising pipeline that includes several clinical-stage programs such as Obe-cel, AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. Despite challenges related to cost of goods sold and potential payer reimbursement issues, positive indicators such as the favorable treatment expected for Obe-cel suggest strong demand from payors. Moreover, mechanistic advantages may enhance Obe-cel's efficacy over existing therapies, adding to the company’s potential for long-term success in the competitive CAR-T market.
Bears say
Autolus Therapeutics has experienced a significant reduction in its sales estimate for obe-cel, with projections decreasing from $83 million to $27 million due to delays in revenue recognition and a pushback of expected EU sales to 2026. This adjustment reflects broader market concerns about the ability of the company's CAR-T therapeutics to meet initial production forecasts, potentially compromising future revenue streams. Additionally, adverse events such as Cytokine release syndrome, neurotoxicity, and severe cytopenias associated with Autolus' therapies may further impede their application and market acceptance, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares